期刊文献+

氯沙坦对高糖诱导大鼠肾近端小管上皮细胞纤溶酶原激活物及其抑制物表达的影响 被引量:2

Effects of Losartan on Expressions of Plasminogen Activator and Plasminogen Activator Inhibitor-1 of Rat Proximal Tubular Epithelial Cells Cultured with High Glucose
下载PDF
导出
摘要 目的研究高糖对正常大鼠肾近端小管上皮细胞纤溶酶原激活物(tPA和uPA)及其抑制物-1(PAI-1)表达的影响,并探讨血管紧张素受体阻滞剂氯沙坦对其改善作用。方法培养大鼠肾近端小管上皮细胞,并分组为正常对照组、甘露醇组(5 mmol/L D-葡萄糖+25 mmol/L甘露醇)、高糖组(30 mmol/L D-葡萄糖)、氯沙坦组(10-3mmol/L氯沙坦)、高糖+氯沙坦组(30 mmol/L D-葡萄糖+10-3mmol/L氯沙坦)。RT-PCR法检测各组细胞tPA、uPA及PAI-1 mRNA表达。结果与正常对照组比较,高糖组肾小管上皮细胞tPA和uPA mRNA表达下降(P<0.01),PAI-1 mRNA表达增加(P<0.01);氯沙坦可部分逆转高糖的作用,高糖加氯沙坦组tPA、uPA表达分别是高糖组的2.06倍、1.69倍(P<0.01),PAI-1表达为高糖组的44%(P<0.01)。结论高糖可使肾近端小管上皮细胞PA/PAI-1 mRNA异常表达,氯沙坦可以在肾小管中通过维持PA/PAI-1的平衡,对糖尿病肾病防治起一定的作用。 Objective To investigate the effects of high glucose on expressions of plasminogen activator(PA) and plasminogen activator inhibitor-1(PAI-1) of rat proximal tubular epithelial cells,and the role of angiotensin Ⅱ receptor antagonist Losartan.Methods The cultured NRK-52E cells(a renal proximal tubular epithelial cell line of rat origin) were divided into five groups: control group,mannitol group(5 mmol/L D-glucose plus 25 mmol/L mannitol),high glucose group(30 mmol/L D-glucose),losartan group(10^-3 mmol/L losartan),high glucose plus losartan group(30 mmol/L D-glucose plus 10^-3 mmol/L losartan).Semi-quantity RT-PCR was used to detect the expression of PA/PAI-1 mRNA.Results Compared with control group,the high glucose group decreased the expressions of tissue plasminogen activator(tPA) and urokinase plasminogen activator(uPA) mRNAs(P〈0.01) and increased PAI-1 mRNA expression(P〈0.01) in cultured NRK-52E cells.Losartan could reverse partly the expression of PA/PAI-1 mRNA.Compared to high glucose group,the PA mRNA expression was significantly increased(P〈0.01) and the PAI-1 mRNA expression was decreased greatly(P〈0.01) to high glucose plus losartan group.Conclusion The abnormal expression of PA/PAI-1 mRNA may play an important role in the accumulation of extracellular matrix(ECM) of diabetic nephropathy(DN).Losartan may keep the balance of PA/PAI-1 and have a protective effect on DN.
出处 《四川大学学报(医学版)》 CAS CSCD 北大核心 2007年第5期813-815,共3页 Journal of Sichuan University(Medical Sciences)
关键词 糖尿病肾病 纤溶酶原激活物 1型纤溶酶原激活物抑制物 氯沙坦 Diabetic nephropathy Plasminogen activator Plasminogen activator inhibitor-1 Losartan
  • 相关文献

参考文献8

  • 1Gunter W,Fuad NZ.Molecular mechanisms of diabetic renal hypertrophy.Kidney Int,1999;56(2):393-405.
  • 2Baricos WH,Reed JC,Cortez SL.Extracellular matrix degradation by cultured mesangial cells:mediators and modulators.Exp Biol Med,2003;228(9):1018-1022.
  • 3Lewis EJ,Hunsick LG,Clarke WR,et al.Renoprotective effect of the angitensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.New Engl J med,2001;345(12):851-860.
  • 4Rice EK,Tesch GH,Cao Z,et al.Induction of MIF synthesis and secretion by tubular epithelialcells:a novel action of angiotensin Ⅱ.Kidney International,2003;3(4):1265-1275.
  • 5Hagiwarn H,Kaizu K,Uriu K,et al.Expression of type-1 plasminogen activator inhibitor in the kidney of diabetic rat models.Thromb Res,2003;111(4-5):301-309.
  • 6Hirano T,Kashiwazaki K,Moritomo Y,et al.Albuminuria is directly associated with incresed plasma PAI-1 and factor Ⅶ level in NIDDM patients.Diabetes Res Clin Pract,1997;37(suppl):11-18.
  • 7陈丽萌,李学旺,黄利伟,李艳.2型糖尿病小鼠肾脏纤溶酶原激活物抑制物-1表达[J].中国医学科学院学报,2005,27(3):344-348. 被引量:7
  • 8Leehey DJ,Singh AK,Alavi N,et al.Role of angiotensin Ⅱ in diabetic nephropathy.Kidney int,2000;7(suppl):93-98.

二级参考文献6

共引文献6

同被引文献27

  • 1张春,孟宪芳,朱忠华,杨晓,邓安国.Role of connective growth factor in plasminogen activator inhibitor-1 and fibronectin expression induced by transforming growth factor β1 in renal tubular cells[J].Chinese Medical Journal,2004(7):990-996. 被引量:20
  • 2史丽谨,朱晓云,刘喜明.丹参素对糖尿病脑梗塞大鼠t-PA、PAI-I含量及mRNA表达的影响[J].临床药物治疗杂志,2007,5(4):40-44. 被引量:9
  • 3Sobel BE,Tilton L,Neimane D,et al.Increased tissue-type plasminogen activator:a facade in the fibrinolytic system in type 2 diabetes.Coron Artery Dis,2005,16(1):31-35.
  • 4Meigs JB,O'Donnell CJ,Tofler GH,et al.Hemostatic markers of endothelial dysfunction and risk of incident type 2 diabetes:the Framingham Offspring Study.Diabetes,2006,55(2):530-537.
  • 5Mouquet F,Cuilleret F,Susen S,et al.Metabolic syndrome and collateral vessel formation in patients with documented occluded coronary arteries:association with hyperglycaemia,insulin-resistance,adiponectin and plasminogen activator inhibitor-1.Eur Heart J,2009,30(7):840-849.
  • 6Le DS,Miles R,Savage PJ,et al.The association of plasma fibrinogen concentration with diabetic microvascular complications in young adults with early-onset of type 2 diabetes.Diabetes Res Clin Pract,2008,82(3):317-323.
  • 7Huang Y,Border WA,Yu L,et al.A PAl-1 mutant,PAI-1R,slows progression of diabetic nephropathy.J Am Soc Nephrol,2008,19(2):329-338.
  • 8Samad F,Pandey M,Bell PA,et al.Insulin continues to induce plasminogen activator inhibitor 1 gene expression in in.sulin-resistant mice and adipoeytes.Mol Med,2000,6(8):680-692.
  • 9Ersoy C,Kiyiei S,Budak F,et al.The effeet of metformin treafment on VEGF and PAI-1 levels in obese type 2 diabetic patients.Diabetes Res Clin Pract,2008,81 (1):56-60.
  • 10Pruski M,Krysiak R,Okopien B,et al.Pleiotropic Action of Short-Term Metformin and Fenofibrate Treatment,Combined With Lifestyle Intervention,in Type 2 Diabetic Patients With Mixed Dyslipidemia.Diabetes Care,2009,32(8):1421-1424.

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部